Tissue Sample Collection From Patients With Fanconi Anemia
This study has been completed.
Sponsor:
OHSU Knight Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT00899522
First received: May 9, 2009
Last updated: May 16, 2014
Last verified: May 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Collecting and storing samples of tumor tissue from patients with Fanconi anemia to test in the laboratory may help the study of cancer in the future.
PURPOSE: This laboratory study is collecting and storing tumor tissue samples from patients with Fanconi anemia.
| Condition | Intervention |
|---|---|
|
Fanconi Anemia Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Other: biologic sample preservation procedure Procedure: biopsy |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | Fanconi Anemia Cancer Cell Repository |
Resource links provided by NLM:
Genetics Home Reference related topics:
Fanconi anemia
MedlinePlus related topics:
Anemia
Genetic and Rare Diseases Information Center resources:
Fanconi Anemia
Congenital Aplastic Anemia
Fanconi Syndrome
Nephropathic Cystinosis
Primary Fanconi Syndrome
U.S. FDA Resources
Further study details as provided by OHSU Knight Cancer Institute:
Primary Outcome Measures:
- Creation of a Fanconi Anemia Cell Repository using rare solid tumor samples from patients with Fanconi anemia [ Time Frame: Duration of the study ]
- Study tissue samples by molecular methods, including gene microarrays [ Time Frame: Duration of the study ]
- Development of cancer cell lines from tissue archived from patients with Fanconi anemia [ Time Frame: Duration of the study ]
| Enrollment: | 8 |
| Study Start Date: | August 2005 |
| Study Completion Date: | May 2013 |
| Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Other: biologic sample preservation procedure
Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
Procedure: biopsy
Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
OBJECTIVES:
- Acquire rare solid tumor samples from patients with Fanconi anemia in order to create a Fanconi Anemia Cell Repository at the Oregon Health and Science University Cancer Institute.
- Study repository tissue using a variety of molecular methods, including gene microarrays.
- Develop cancer cell lines that are publicly available from tissue archived from patients with Fanconi anemia.
OUTLINE: Tumor biopsies are collected from patients with Fanconi anemia and archived for future molecular studies, cell line generation, and general usage by the research community at large. Medical information about the patient's cancer is also archived.
PROJECTED ACCRUAL: Not specified.
Eligibility| Ages Eligible for Study: | 1 Year to 55 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
To recruit participants into this project, an announcement will be posted on the Fanconi Anemia Research Fund website (http://www.fanconi.org/) after IRB approval is obtained.
Criteria
DISEASE CHARACTERISTICS:
- Confirmed Fanconi anemia
- Confirmed malignant solid tumor
- Biopsy of tumor tissue available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899522
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899522
Locations
| United States, Oregon | |
| Knight Cancer Institute at Oregon Health and Science University | |
| Portland, Oregon, United States, 97239-3098 | |
Sponsors and Collaborators
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Grover C. Bagby, MD | OHSU Knight Cancer Institute |
More Information
| Responsible Party: | OHSU Knight Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT00899522 History of Changes |
| Other Study ID Numbers: |
CDR0000445453 P30CA069533 ( US NIH Grant/Contract Award Number ) OHSU-HEM-03022-LX OHSU-IRB00001100 OSHU-CR00003822 |
| Study First Received: | May 9, 2009 |
| Last Updated: | May 16, 2014 |
Keywords provided by OHSU Knight Cancer Institute:
|
Fanconi anemia unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific |
Additional relevant MeSH terms:
|
Anemia Fanconi Anemia Anemia, Hypoplastic, Congenital Anemia, Aplastic Neoplasms Fanconi Syndrome Hematologic Diseases Bone Marrow Diseases |
Genetic Diseases, Inborn DNA Repair-Deficiency Disorders Metabolic Diseases Renal Tubular Transport, Inborn Errors Kidney Diseases Urologic Diseases Metabolism, Inborn Errors |
ClinicalTrials.gov processed this record on May 24, 2017